文献速递临床试验与 GCP

自体条件血清疗法(Orthokine®)对慢性神经根痛患者背根神经节的疗效:前瞻性随机安慰剂对照双盲临床试验(RADISAC试验)研究方案

Efficacy of conditioned autologous serum therapy (Orthokine®) on the dorsal root ganglion in patients with chronic radiculalgia: study protocol for a prospective randomized placebo-controlled double-blind clinical trial (RADISAC trial).
PubMed 文献 · Trials · 2023-11-25

本研究为前瞻性随机双盲安慰剂对照试验方案,拟纳入70例持续≥6个月且对任何治疗无效的下肢神经根痛患者,按1:1随机接受脉冲射频(PRF)联合自体条件血清(ACS)或PRF联合0.9%生理盐水,主要终点为12个月时NPRS应答者比例(降低≥2分),次要终点为ODS应答者比例(改善≥10分)。

要点

  • 拟纳入70例持续≥6个月且对任何治疗无效的下肢神经根痛患者,每组35例。
  • 两组均先接受背根神经节PRF治疗,再分别注射ACS或0.9%生理盐水。
  • 主要终点为12个月时NPRS降低≥2分的应答者比例,次要终点为ODS改善≥10分的应答者比例。

核心结论

  • 该前瞻性双盲随机安慰剂对照研究旨在为ACS改善下肢神经根痛患者神经病理性症状的安全性和有效性提供I级证据。

研究设计与样本

  • 前瞻性随机安慰剂对照双盲临床试验方案,拟纳入70例持续≥6个月且对任何治疗无效的下肢神经根痛患者,按1:1随机分为PRF联合ACS组(实验组)和PRF联合0.9%生理盐水组(安慰剂组),每组35例。
  • 两组均在注射样本(对照或安慰剂)前接受背根神经节PRF治疗。
  • 评估时间点为基线、治疗后1个月、3个月、6个月和12个月。
  • 试验注册号EUDRACT 2021-005124-38,验证日期2021年11月13日,本稿件为方案第2版。

关键数值与推荐

  • 主要疗效指标为基线至12个月随访时NPRS应答者比例,采用经验证的最小重要变化(MIC)阈值,NPRS降低≥2分视为有临床意义的疼痛缓解。
  • 次要疗效指标为基线至12个月随访时ODS应答者比例,实验组(PRF联合ACS)与安慰剂组(PRF联合0.9%生理盐水)比较,ODS应答者定义为ODS较基线改善≥10分(经验证MIC)作为临床显著疗效阈值。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Pulsed radiofrequency (PRF) treatment on the dorsal root ganglion (DRG) has been proposed as a good option for the treatment of persistent radicular pain based on its effect of neuromodulation on neuropathic pain. Autologous conditioned serum (ACS) therapy is a conservative treatment based on the patient's own blood. The aim of this manuscript is to develop a study protocol using ACS on the DRG as a target for its molecular modulation. METHODS: We plan to conduct a randomized controlled study to compare the efficacy of PRF therapy plus ACS versus PRF therapy plus physiological saline 0.9% (PhS) on the DRG to reduce neuropathic pain in patients with persistent lower limb radiculalgia (LLR) and to contribute to the functional improvement and quality of life of these patients. Study participants will include patients who meet study the inclusion/exclusion criteria. Eligible patients will be randomized in a 1:1 ratio to one of treatment with PRF plus ACS (experimental group) or PRF plus PhS (placebo group). The study group will consist of 70 patients (35 per group) who have experienced radicular pain symptoms for ≥ 6 months' duration who have failed to respond to any therapy. Both groups will receive PRF on the DRG treatment before the injection of the sample (control or placebo). Patient assessments will occur at baseline, 1 month, 3 months, 6 months, and 12 months after therapy. The primary efficacy outcome measure is Numeric Pain Rating Scale (NPRS) responders from baseline to 12 months of follow-up using validated minimal important change (MIC) thresholds. A reduction of ≥ 2 points in NPRS is considered a clinically significant pain relief. The secondary efficacy outcome measure is the proportion of Oswestry Low Back Pain Disability Scale (ODS) responders from baseline to 12 months of follow-up in the experimental group (PRF plus ACS) versus the placebo group (PRF plus PhS). ODS responders are defined as those patients achieving the validated MIC of ≥ 10-point improvement in ODS from baseline to 12 months of follow-up as a clinically significant efficacy threshold. DISCUSSION: This prospective, double-blind, randomized placebo-controlled study will provide level I evidence of the safety and effectiveness of ACS on neuropathic symptoms in LLR patients. TRIAL REGISTRATION {2A}{2B}: EUDRACT number: 2021-005124-38. Validation date: 13 November 2021. Protocol version {3}: This manuscript presents the 2nd protocol version.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Homs M, Milà R, Valdés R, et al. Efficacy of conditioned autologous serum therapy (Orthokine®) on the dorsal root ganglion in patients with chronic radiculalgia: study protocol for a prospective randomized placebo-controlled double-blind clinical trial (RADISAC trial). Trials. 2023. PMID: 38007491. doi:10.1186/s13063-023-07787-y

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。